Furthermore, translational research in ARDS patients randomized to methylprednisolone has demonstrated the ability of corticosteroid therapy to rescue the cellular concentrations and functions of activated Glucocorticoid Receptors GRα (GC-GRα) leading to downregulation of systemic and pulmonary NF-κB-activated markers of inflammation, coagulation, and fibroproliferation [51,52,53]. Here, NFKB1 is linked to acute respiratory distress syndrome.